Elicio Therapeutics Inc expected to post a loss of $1.09 a share - Earnings Preview
Elicio Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Elicio Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
Brief: Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic's Solid Tumor Study Of Eli-002
Brief: Elicio Therapeutics Presents Updated Preliminary Data From The Early-Stage Study Of Eli-002 At Aacr Special Conference Pancreatic Cancer
Brief: Elicio Therapeutics Completes Reverse Merger And Provides Corporate Update
Brief: Elicio Therapeutics Says Positive Interim Data From Phase 1 Study Of Investigational Therapeutic Cancer Immunotherapy, ELI-002, In Patients With High Relapse Risk Pancreatic And Colorectal Cancer
U.S. STOCKS ON THE MOVE-Lands' End, Energy sector
U.S. STOCKS ON THE MOVE-Biogen, NetApp, LyondellBasell
Angion rises after plan for 1-for-10 reverse stock split
Brief: Angion Biomedia Corp. Announces 1-For-10 Reverse Stock Split
Brief: Elicio Therapeutics Says First Patient Dosed In Phase 1/2 Study Of Lymph Node-Targeted Investigational Therapeutic Vaccine
Brief: Angion Biomedica Corp On March 9, 2023 Co Novapark Entered Deal Which Terminated Agreement Of Lease, Dated As Of June 21, 2011 - SEC Filing
U.S. STOCKS ON THE MOVE-Chord Energy, Kroger, PetMed Express
U.S. STOCKS ON THE MOVE-DoorDash, Walt Disney, Tesla
U.S. STOCKS ON THE MOVE-Papa John's, Whirlpool, Coca-Cola
Angion Biomedica tanks on merger deal with Elicio Therapeutics
Brief: Elicio To Merge With A Wholly-Owned Unit Of Angion In An All-Stock Transaction
Brief: Angion Says Receives Nasdaq Notice Regarding Minimum Bid Price Requirements